Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:TH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(186)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Jun 01, 2024 10:25am
RE:Progression free survival rate
Do we have something on their posters... something like those compelling news that could make us richer than 40 cents....
(289)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on Jun 01, 2024 9:40am
Progression free survival rate
This bispecific antibody stops immunosuppression and blood supply process both responsible for progression of the cancer. The drug is now approved in combo therapy for cancer in
...more
(186)
•••
Trogarzon
X
View Profile
View Bullboard History
Post by
Trogarzon
on May 31, 2024 4:04pm
Pouet Pouet week again
Tomorrow ASCO.. last call for a partner and another dilution... Q2 sales should be good... lol...
(2)
•••
CreatingApe
X
View Profile
View Bullboard History
Post by
CreatingApe
on May 30, 2024 3:46pm
Wino?
I understand why you have been taking a break from this board. Trust me. But are you still in this with us? Miss all of your input, hope you are well and that you are just avoiding this messaging
...more
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on May 30, 2024 5:01am
Buzz on the Bullboards: Volatility persists in the face of economic indicators
Canada’s main stock index struggled and the NASDAQ hit a high, demonstrating a continued appetite for tech stocks amidst market volatility.
read article.
(186)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 28, 2024 12:33pm
RE:RE:RE:Market does know how to value biotech companies. See below
Most second hand opinions I get from onco specialists is that the revised protocol will probably yield much better efficacity. The odds are on our side it seems.
(26)
•••
Momo25
X
View Profile
View Bullboard History
Comment by
Momo25
on May 28, 2024 11:28am
RE:RE:Market does know how to value biotech companies. See below
Maybe the market got it wrong with Thera because it is hard to get it right with this kind of management. Anyway, what I try to say is don't be so excited with the current outcome, we don
...more
(186)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 28, 2024 8:55am
RE:Market does know how to value biotech companies. See below
Just saying the market got it wrong with Thera in 2010, 2014 and 2018... by a mile. Taling 20 cents to 15$ wrong.
(26)
•••
Momo25
X
View Profile
View Bullboard History
Post by
Momo25
on May 27, 2024 11:56pm
Market does know how to value biotech companies. See below
The Best Biotech Stocks of May 2024 Company (TICKER) 5-Year Average Annual EPS Forecast
...more
(98)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 27, 2024 6:31pm
RE:RE:ASCO Info
I had my contact at GSK put a recent phase two result through my AI model this AM and it said it was not good enough to move forward - and that is the case in their phase 2 example. So it's pretty
...more
(49)
•••
Qwerty54321
X
View Profile
View Bullboard History
Comment by
Qwerty54321
on May 27, 2024 5:27pm
RE:ASCO Info
One thing the AI didn't pick up is the analysis is for a SUBSET of all treated patient. I'm not going to go back and check the PR but it's something like 3 "women's" cancers,
...more
(186)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 27, 2024 2:51pm
RE:It's about trust
In the mean time the market as you call it with all it's mighty intelligencia (the market is always wright the saying goes) buys Trump media and Gamestop. Apart from our dear management
...more
(26)
•••
Momo25
X
View Profile
View Bullboard History
Post by
Momo25
on May 27, 2024 2:46pm
It's about trust
Th management and the CEO have overwhelmigly lied in the past so nobody trust them anymore. Hence, whatever the results might be of interest they are not making the market moving to the right
...more
(98)
•••
Mannequin
X
View Profile
View Bullboard History
Post by
Mannequin
on May 27, 2024 8:09am
AI Conclusion of Abstract
### Interpretation and Considerations 1. **Efficacy:** - The stabilization of disease in a heavily pretreated population, along with a partial response and complete response
...more
(98)
•••
Mannequin
X
View Profile
View Bullboard History
Post by
Mannequin
on May 27, 2024 8:04am
ASCO Info
I let the most advanced AI that I have access to review several ASCO abstracts from other companies. It concluded that these other companies were not really getting the results necessary in the
...more
(98)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 26, 2024 2:26pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
It is sad it potentially could have helped, and I wonder if anyone else in her situation has been put through the program with ovarian cancer and seen any benefit. There is not much explained thus far
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Nanalysis Scientific Corp. Announces First Quarter 2024 Results
This Small-Cap Gold Stock Jumped Almost 50% on Friday